Analyst: Riata Ruckus Won’t Hurt CRM Market Long-Term

The high-profile furor over St. Jude Medical’s recalled Riata defibrillator leads last week won’t have a lasting impact on the overall cardiac rhythm management market, said Barclays Capital analyst Adam Feinstein.
Mass Device